Tvardi Therapeutics Inc (TVRD)

$2.63 -0.04 (-1.50%)
Market Cap 25.05M
Revenue (ttm) 0.00
Net Income (ttm) -18.21M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 39,700
Avg Vol 49,600
Day's Range N/A - N/A
Shares Out 9.38M
Stochastic %K 11%
Beta 0.33
Analysts Sell
Price Target $8.29

Company Profile

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis...

Industry: Biotechnology
Sector: Healthcare
Phone: 713 489 8654
Address:
3 Sugar Creek Center Boulevard, Suite 525, Sugar Land, United States
Estimize
Estimize Jun. 15 at 1:06 PM
Wall St is expecting -0.70 EPS for $TVRD Q2 [Reporting 08/13 BMO] http://www.estimize.com/intro/tvrd?chart=historical&metric_name=eps&utm_c
0 · Reply
manishc0727
manishc0727 Jun. 12 at 7:25 PM
$TVRD waiting on this to come to $10 so I can break even
0 · Reply
aletz
aletz Jun. 11 at 6:44 PM
$TVRD https://www.biostockinfo.com/biotech-catalyst-ai-scanner-june-wk3/ Picked as #7 pick this week from my AI Catalyst Scanner , Visit the link for more info. and catalyst driven investment ideas. Always do your own DD.
0 · Reply
BPharmCatalyst
BPharmCatalyst May. 15 at 3:23 PM
Biotech volatility is heating up into quarter end 🚨 These 3 upcoming Phase 1 catalysts could have major valuation implications for the companies behind them: $TVRD — STAT3 inhibitor safety + PK data $ANTX — Chagas disease curative potential $CAPR — StealthX exosome vaccine platform data Watch the full Weekly Watchlist Speed Run👇 https://www.youtube.com/@BioPharmCatalyst/shorts #Biotech #Stocks #Investing #ClinicalTrials #FDA #Shorts
0 · Reply
MoneyorBagHolder
MoneyorBagHolder May. 12 at 11:28 AM
$TVRD Apparently $TVRD reported Q1 2026 earnings Has anyone looked into this for potential breakout? If you look say the one year graph, there was a high degree of confidence on the stock and afterwards it dropped dramatically.
0 · Reply
focafoca99
focafoca99 May. 8 at 11:30 AM
$TVRD disclosed its Q1 2026 results and business highlights.
0 · Reply
MoneyorBagHolder
MoneyorBagHolder May. 7 at 7:54 PM
$TVRD I am seeing earnings release on May 11, May 13, and May 19 (depending on what platform….) Nice increase today but where’s the news to justify the increase?
1 · Reply
Fakhrul123
Fakhrul123 May. 7 at 7:27 PM
$TVRD holding patiently for $15
0 · Reply
manishc0727
manishc0727 May. 7 at 6:34 PM
$TVRD come on give me my $10 so I can break even
0 · Reply
SuperGreenToday
SuperGreenToday May. 6 at 8:59 PM
$TVRD Share Price: $3.67 Contract Selected: Sep 18, 2026 $5 Calls Buy Zone: $0.34 – $0.42 Target Zone: $0.57 – $0.70 Potential Upside: 58% ROI Time to Expiration: 134 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Latest News on TVRD
Tvardi Therapeutics initiated with a Buy at H.C. Wainwright

2026-06-08T10:20:08.000Z - 8 days ago

Tvardi Therapeutics initiated with a Buy at H.C. Wainwright

Tvardi Therapeutics to Participate in Upcoming Investor Events

May 21, 2026, 8:00 AM EDT - 26 days ago

Tvardi Therapeutics to Participate in Upcoming Investor Events

Tvardi Therapeutics reports Q1 EPS (73c), consensus (72c)

2026-05-08T11:14:39.000Z - 5 weeks ago

Tvardi Therapeutics reports Q1 EPS (73c), consensus (72c)

Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update

May 8, 2026, 7:00 AM EDT - 5 weeks ago

Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update

Tvardi Therapeutics files $200M mixed securities shelf

2026-05-01T20:11:24.000Z - 6 weeks ago

Tvardi Therapeutics files $200M mixed securities shelf

Tvardi Therapeutics downgraded to Underweight from Equal Weight at Barclays

2026-04-20T09:26:43.000Z - 2 months ago

Tvardi Therapeutics downgraded to Underweight from Equal Weight at Barclays

Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium

Apr 2, 2026, 8:00 AM EDT - 2 months ago

Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium

Tvardi Therapeutics price target lowered to $3 from $4 at Piper Sandler

2026-04-01T11:13:02.000Z - 2 months ago

Tvardi Therapeutics price target lowered to $3 from $4 at Piper Sandler

Tvardi Therapeutics price target lowered to $4 from $5 at Barclays

2026-04-01T10:34:44.000Z - 2 months ago

Tvardi Therapeutics price target lowered to $4 from $5 at Barclays

Tvardi Therapeutics reports Q4 EPS (78c), consensus (57c)

2026-03-31T20:06:37.000Z - 2 months ago

Tvardi Therapeutics reports Q4 EPS (78c), consensus (57c)

Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update

Mar 31, 2026, 4:01 PM EDT - 2 months ago

Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update

Tvardi Therapeutics upgraded to Buy from Neutral at Lucid Capital

2026-02-04T11:11:35.000Z - 4 months ago

Tvardi Therapeutics upgraded to Buy from Neutral at Lucid Capital

Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 8, 2026, 4:05 PM EST - 5 months ago

Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Tvardi Therapeutics announces further Phase 2 REVERT IPF data

2026-01-08T13:25:58.000Z - 5 months ago

Tvardi Therapeutics announces further Phase 2 REVERT IPF data

Tvardi Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 18, 2025, 8:00 AM EST - 7 months ago

Tvardi Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Tvardi Therapeutics reports Q3 EPS (59c), consensus (96c)

2025-11-13T21:06:01.000Z - 7 months ago

Tvardi Therapeutics reports Q3 EPS (59c), consensus (96c)

Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update

Nov 13, 2025, 4:01 PM EST - 7 months ago

Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update

Tvardi Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Nov 4, 2025, 8:00 AM EST - 8 months ago

Tvardi Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Tvardi downgraded to Market Perform from Outperform at Raymond James

2025-10-14T11:00:22.000Z - 8 months ago

Tvardi downgraded to Market Perform from Outperform at Raymond James

Tvardi Therapeutics downgraded to Equal Weight from Overweight at Barclays

2025-10-13T20:15:10.000Z - 8 months ago

Tvardi Therapeutics downgraded to Equal Weight from Overweight at Barclays

Cantor downgrades Tvardi Therapeutics, sees ‘no path forward in IPF’

2025-10-13T14:35:06.000Z - 8 months ago

Cantor downgrades Tvardi Therapeutics, sees ‘no path forward in IPF’

Tvardi Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald

2025-10-13T14:15:14.000Z - 8 months ago

Tvardi Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald

Tvardi Therapeutics downgraded to Neutral from Overweight at Piper Sandler

2025-10-13T14:10:07.000Z - 8 months ago

Tvardi Therapeutics downgraded to Neutral from Overweight at Piper Sandler

Why Is Tvardi Therapeutics Stock (TVRD) Down 85% Today?

2025-10-13T12:53:44.000Z - 8 months ago

Why Is Tvardi Therapeutics Stock (TVRD) Down 85% Today?

Tvardi says benefit of TTI-101 treatment not observed in REVERT trial

2025-10-13T11:51:36.000Z - 8 months ago

Tvardi says benefit of TTI-101 treatment not observed in REVERT trial

Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis

Oct 13, 2025, 7:30 AM EDT - 8 months ago

Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis

Tvardi Therapeutics to Participate in the Cantor Global Healthcare Conference

Aug 21, 2025, 8:00 AM EDT - 10 months ago

Tvardi Therapeutics to Participate in the Cantor Global Healthcare Conference

Tvardi Therapeutics Announces Second Quarter 2025 Results and Provides Business Update

Aug 14, 2025, 4:01 PM EDT - 10 months ago

Tvardi Therapeutics Announces Second Quarter 2025 Results and Provides Business Update

Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

Jul 15, 2025, 8:00 AM EDT - 1 year ago

Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis

May 27, 2025, 8:00 AM EDT - 1 year ago

Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis

Tvardi Therapeutics to Participate in Upcoming Investor Conferences

May 20, 2025, 8:00 AM EDT - 1 year ago

Tvardi Therapeutics to Participate in Upcoming Investor Conferences

Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update

May 13, 2025, 4:05 PM EDT - 1 year ago

Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update

Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference

May 6, 2025, 7:00 AM EDT - 1 year ago

Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference

Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics

Apr 15, 2025, 4:05 PM EDT - 1 year ago

Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics

CARA

Estimize
Estimize Jun. 15 at 1:06 PM
Wall St is expecting -0.70 EPS for $TVRD Q2 [Reporting 08/13 BMO] http://www.estimize.com/intro/tvrd?chart=historical&metric_name=eps&utm_c
0 · Reply
manishc0727
manishc0727 Jun. 12 at 7:25 PM
$TVRD waiting on this to come to $10 so I can break even
0 · Reply
aletz
aletz Jun. 11 at 6:44 PM
$TVRD https://www.biostockinfo.com/biotech-catalyst-ai-scanner-june-wk3/ Picked as #7 pick this week from my AI Catalyst Scanner , Visit the link for more info. and catalyst driven investment ideas. Always do your own DD.
0 · Reply
BPharmCatalyst
BPharmCatalyst May. 15 at 3:23 PM
Biotech volatility is heating up into quarter end 🚨 These 3 upcoming Phase 1 catalysts could have major valuation implications for the companies behind them: $TVRD — STAT3 inhibitor safety + PK data $ANTX — Chagas disease curative potential $CAPR — StealthX exosome vaccine platform data Watch the full Weekly Watchlist Speed Run👇 https://www.youtube.com/@BioPharmCatalyst/shorts #Biotech #Stocks #Investing #ClinicalTrials #FDA #Shorts
0 · Reply
MoneyorBagHolder
MoneyorBagHolder May. 12 at 11:28 AM
$TVRD Apparently $TVRD reported Q1 2026 earnings Has anyone looked into this for potential breakout? If you look say the one year graph, there was a high degree of confidence on the stock and afterwards it dropped dramatically.
0 · Reply
focafoca99
focafoca99 May. 8 at 11:30 AM
$TVRD disclosed its Q1 2026 results and business highlights.
0 · Reply
MoneyorBagHolder
MoneyorBagHolder May. 7 at 7:54 PM
$TVRD I am seeing earnings release on May 11, May 13, and May 19 (depending on what platform….) Nice increase today but where’s the news to justify the increase?
1 · Reply
Fakhrul123
Fakhrul123 May. 7 at 7:27 PM
$TVRD holding patiently for $15
0 · Reply
manishc0727
manishc0727 May. 7 at 6:34 PM
$TVRD come on give me my $10 so I can break even
0 · Reply
SuperGreenToday
SuperGreenToday May. 6 at 8:59 PM
$TVRD Share Price: $3.67 Contract Selected: Sep 18, 2026 $5 Calls Buy Zone: $0.34 – $0.42 Target Zone: $0.57 – $0.70 Potential Upside: 58% ROI Time to Expiration: 134 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
MoneyorBagHolder
MoneyorBagHolder Apr. 17 at 3:58 PM
$TVRD Anyone seen an update on $TVRD participation at Raymond James Biotech Innovation Symposium in New York City, on April 14th, 2026?
0 · Reply
Fakhrul123
Fakhrul123 Apr. 16 at 4:49 AM
$TVRD $10 in a month or so
1 · Reply
Estimize
Estimize Apr. 1 at 12:06 PM
$TVRD reported YoY EPS growth for Q4, 89.07% in Q3. http://www.estimize.com/intro/tvrd?chart=historical&metric_name=eps&utm_content=TVRD&
0 · Reply
Estimize
Estimize Apr. 1 at 12:03 AM
$TVRD reported -0.78 EPS and 0.00 revenue for Q4. http://www.estimize.com/intro/tvrd?chart=historical&metric_name=eps&utm_content=TVRD&utm_
0 · Reply
OnceBroke_nowAbroker
OnceBroke_nowAbroker Mar. 26 at 12:45 PM
$VRTX $TVRD $MBOT ONLY 66 WATCHERS IPO RECEIVED U.S PATENT FOR FIBROSIS AN HOUR AGO. GET IN EARLY ----------> $AGMB
1 · Reply
RajDude
RajDude Mar. 25 at 3:35 PM
$TVRD when is earnings?
0 · Reply
Estimize
Estimize Mar. 24 at 12:03 PM
Wall St is expecting -0.65 EPS for $TVRD Q4 [Reporting 04/01 AMC] http://www.estimize.com/intro/tvrd?chart=historical&metric_name=eps&utm_c
0 · Reply
MoneyorBagHolder
MoneyorBagHolder Mar. 10 at 1:59 PM
$TVRD Barclays 28th Annual Global Healthcare Conference Format: Fireside chat Date: Tuesday, March 10, 2026 Time: 2:00 PM EST Location: Miami Beach, FL https://ir.tvarditherapeutics.com/investor-relations
0 · Reply
Fakhrul123
Fakhrul123 Feb. 26 at 10:36 PM
$TVRD go back to $40
1 · Reply